相关实验视频
Updated: Jan 16, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
在生物经验的炎症性肠病中Upadacitinib:现实世界的有效性,安全性和实验室结果
1Department of Internal Medicine (Gastroenterology), Faculty of Medicine, Mersin University, 33343 Mersin, Turkey.
乌帕达西替尼在炎症性肠病 (IBD) 患者中显示出现实世界的有效性,这些患者之前的生物治疗失败了. 简氏激酶 (JAK) 抑制剂改善了症状和炎症标志物,没有显著的安全问题或负面的代谢影响.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学 是一个学科.
- 临床医学 临床医学
背景情况:
- 乌帕达西丁 (Upadacitinib) 是一种Janus激酶 (JAK) 抑制剂,已被批准用于炎症性肠病 (IBD).
- 有限的现实世界数据存在于IBD的有效性,安全性和实验室效果.
- 这项研究评估了Upadacitinib在具有克罗恩病 (CD) 和性结肠炎 (UC) 的生物经验的患者中.
研究的目的:
- 评估Upadacitinib在中度至重度的CD和UC中的实际有效性和安全性.
- 评估药物对IBD患者实验室参数的影响.
- 分析先前用生物制剂治疗的患者的结局.
主要方法:
- 对22名UC和19名CD患者进行了回顾性队列研究,这些患者接受了Upadacitinib≥6个月.
- 使用哈维 - 布拉德肖指数 (HBI) 评估CD和部分梅奥得分 (PMS) 评估UC.
- 在基线,3个月和6个月进行的评估.
主要成果:
- 6个月的高持续率:CD的78.3%,UC的88%.
- 临床响应率: 72.7% (CD) 和 83.3% (UC). 临床响应率: 72.7% (CD) 和 83.3% (UC). 临床响应率: 72.7% (CD) 和 83.3% (UC).
- 临床缓解率:50% (CD) 和58.3% (UC).
- 便中calprotectin和C反应蛋白的显著减少 (p < 0.001).
- 总,LDL和HDL胆固醇增加;甘油三或LDL/HDL比率没有变化.
- 没有观察到任何显著的不良事件,心血管事件或死亡.
结论:
- 在生物不响应IBD患者中,upadacitinib是有效的.
- 该药物改善了临床结果和炎症标志物.
- 乌帕达西丁可以增加胆固醇,但不会对葡萄糖代谢或LDL/HDL比率产生负面影响.
- 进一步的长期多中心研究是有必要的.
更多相关视频
08:27Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
Published on: September 20, 2018
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...